Medication-overuse headache: a narrative review.
Helin Gosalia, David Moreno-Ajona, Peter J Goadsby
https://pubmed.ncbi.nlm.nih.gov/38816828/Actively Recruiting
Led by Mahidol University · Updated on 2026-10-08
130
Participants Needed
3
Research Sites
N/A
Total Duration
Migraine is one of the leading causes of disability worldwide and can become more severe when acute medications are overused, resulting in a condition called medication overuse headache MOH. This research evaluates the use of greater occipital nerve block GONB as a treatment to help with detoxification in migraine patients who have MOH. The study aims to demonstrate the effectiveness of GONB in reducing headaches during the withdrawal from overused medications. Participants will be randomly assigned to one of two groups. One group will receive a 4-mL injection containing 2 mL of 2% lidocaine and 2 mL of methylprednisolone 40 mgmL 80 mg, administered at a specific point on the back of the head. The other group will receive a placebo injection of 4 mL normal saline in the same location. This treatment is given as part of the detoxification process to reduce withdrawal headaches. During the study, participants monthly headache days, headache duration and severity, type and frequency of acute medication use, and headache status on a 5-point Likert scale will be tracked. These assessments will occur at 2 weeks and at 1, 2, and 3 months after treatment. The Migraine Disability Assessment MIDAS score will also be measured at the end of the third month. The primary outcome is the percentage of patients with MOH at 1 and 3 months after detoxification.
CONDITIONS
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
P
Pannathat Soontrapa, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mahidol University
Lead Sponsor
Chiang Mai University, Thailand
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive either the greater occipital nerve block injection with lidocaine and methylprednisolone or a placebo saline injection.
Visits at 2 weeks, 1 month, 2 months, and 3 months after treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Helin Gosalia, David Moreno-Ajona, Peter J Goadsby
https://pubmed.ncbi.nlm.nih.gov/38816828/Prut Koonalintip, Katherine Phillips, Benjamin R Wakerley
https://pubmed.ncbi.nlm.nih.gov/39337929/Arman Arab, Masoud Khoshbin, Elham Karimi...
https://pubmed.ncbi.nlm.nih.gov/33945036/Levent Ertugrul Inan, Nurten Inan, Hanzade Aybuke Unal-Artık...
https://pubmed.ncbi.nlm.nih.gov/30612462/Stephen D Silberstein, Joshua M Cohen, Michael J Seminerio...
https://pubmed.ncbi.nlm.nih.gov/32958075/Hans-Christoph Diener, Michael J Marmura, Stewart J Tepper...
https://pubmed.ncbi.nlm.nih.gov/33314079/GBD 2023 Headache Collaborators
https://pubmed.ncbi.nlm.nih.gov/41240916/David W Dodick, Erin G Doty, Sheena K Aurora...
https://pubmed.ncbi.nlm.nih.gov/33143451/Nicolas Vandenbussche, Domenico Laterza, Marco Lisicki...
https://pubmed.ncbi.nlm.nih.gov/30003412/Mahidol University
Lead Sponsor
Chiang Mai University, Thailand
Collaborating Sponsor